Back to search results

Study of Soquelitinib for Moderate to Severe Atopic Dermatitis

This study is evaluating a medication called soquelitinib for adults with moderate to severe atopic dermatitis (AD), also known as eczema. Researchers want to see how well different doses of soquelitinib work compared to a placebo (a pill with no medicine). They will regularly check your skin to track changes in your AD. The study will also look at how safe soquelitinib is by monitoring any side effects and how well participants can tolerate the medication. To join, you must be at least 18 years old and have been diagnosed with AD for at least one year, with moderate to severe symptoms.

Study design
This interventional study plans to enroll 200 participants. It compares soquelitinib tablets to a matching placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, change in Eczema Area and Severity Index (EASI) score, is measured from baseline through Week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07441395

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Recruiting
PHASE2Ages 18+InterventionalTreatment
Corvus Pharmaceuticals, Inc.
~200 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:SoquelitinibPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
Measured over Baseline through Week 12

Conditions

Atopic Dermatitis
Atopic Dermatitis Eczema
Eczema
Eczema, Atopic

Explore related trials

Atopic Dermatitis

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Isin Sinem Bagci, MD · STUDY_DIRECTOR · Corvus Pharmaceuticals, Inc.

Who to contact

Corvus Clinical Trials
[email protected]
650-889-4390
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult male or female, ≥18 years of age, as applicable according to local legislation, at Screening.
Diagnosis of AD with onset of symptoms at least 1 year prior to the Screening visit.
Moderate to severe disease at screening and pre-randomization on Day 1 defined by:
EASI ≥16
Body surface area ≥10%
vIGA ≥3
PP-NRS average score of ≥4 over a period of 7 days prior to randomization at Day 1.
Documented history of prior topical and/or systemic therapy for AD within 6 months of randomization.
A female participant is eligible if she is not pregnant or breastfeeding, and is either of non-childbearing potential, OR of childbearing potential and agrees to use highly effective birth control

Exclusion

Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on AD.
Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 30 days of the Baseline visit or that could interfere with the appropriate assessment of AD lesions.
Known immunodeficiency syndrome, history of an invasive infection or active non skin-related infection requiring systemic anti-infective treatment within 30 days of Baseline.
History of immunosuppression not related to medication, history of clinically significant medical conditions, or any other reason which in the opinion of the investigator would interfere with the participant's participation in this study.
Have an unstable or uncontrolled illness, including but not limited to cerebrocardiovascular, respiratory, gastrointestinal, endocrine, hematologic, or neurologic disorders that would potentially affect participant safety within the study or confound efficacy and safety assessments.

What this trial measures

  • Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12Baseline through Week 12

    EASI is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head and neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.